Latest Commercial Partnerships News

Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.

Vulcan Energy Resources has locked in a €2.2 billion financing package to propel its Phase One Lionheart lithium and renewable energy project in Germany, marking a major step towards Europe’s first fully domestic sustainable lithium supply chain.

Sparc Technologies has marked a significant milestone with sustained hydrogen production at its pioneering pilot plant and secured key patents, while also achieving its first commercial sale of graphene additives.

TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

Decidr AI Industries has solidified its position in the agentic AI market by completing strategic acquisitions and launching its DecidrOS platform, achieving a 60% revenue increase in the December quarter.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

Zeotech Limited has made significant strides in advancing its Toondoon Kaolin Project mining readiness and secured key partnerships to commercialise its AusPozz™ metakaolin product, validated by independent testing.

Li-S Energy has made significant strides in Q4 2025, securing a major government grant, forging key defence partnerships, and commissioning Australia’s first lithium foil production line.

PainChek has secured FDA-regulated medical device status, enabling US Remote Therapeutic Monitoring reimbursement and opening a major US growth avenue. The company targets musculoskeletal pain management in non-verbal dementia patients, a largely underserved market.

Vitrafy Life Sciences has marked significant progress in Q2 FY2026 with a strategic partnership, commercial launch in North America, and advancing clinical trials, underpinning its growth in cryopreservation technology.

NoviqTech Limited has secured a controlling stake in Coralia, an Australian biochar carbon removal company, positioning itself at the forefront of the rapidly expanding carbon dioxide removal market driven by data centre growth.